Senta

Quick links to important sections

Senta

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Senta

What is Senta? Definition and Classification

Property Description
Active ingredient Diflunisal
Form Solid Oral Tablet
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Relief of pain and inflammation
Origin Synthetic

Senta is the trade name for a prescription medication whose single active ingredient is Diflunisal, classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is universally regarded as a non-narcotic analgesic, designed to manage discomfort without the dependence risk associated with opioid medications. It is characterized as a distinctive salicylic acid derivative.

Diflunisal is chemically differentiated from common salicylates like aspirin because it is not metabolized into salicylic acid within the body. This structural difference results in a clinically recognized longer plasma half-life, which supports the drug's design for sustained therapeutic effects, particularly valuable in managing chronic inflammatory states.


The Pharmaceutical Form and Origin of Senta

Senta is provided for patient use as a solid oral tablet, ensuring systemic administration of the active ingredient, Diflunisal, into the bloodstream. The drug itself is entirely synthetic in origin, produced via a chemical synthesis process, and contains the C13H8F2O3 compound. The oral tablet formulation ensures that the medication is readily absorbed throughout the body to exert its effects wherever inflammation or pain is present.


General Purpose: Pain and Inflammation Relief

The primary goal of Senta is to provide comprehensive relief by addressing the chemical processes underlying both mild to moderate pain and persistent inflammation. The established mechanism involves inhibiting the enzymes that produce prostaglandins, which are powerful lipid compounds responsible for initiating swelling and pain in injured or inflamed tissues. The efficacy of Diflunisal as a dual-acting analgesic and anti-inflammatory agent helps patients manage symptoms that restrict their daily activities and mobility, offering a foundational treatment for inflammation-driven discomfort.

Regulatory References

  1. NIH Fact Sheet on Diflunisal

What side effects are possible with Senta?

Possible Side Effects and Safety Information

The safety profile of Senta (Diflunisal), a Nonsteroidal Anti-Inflammatory Drug (NSAID), is officially documented across regulatory systems, addressing both common adverse events and serious risks inherent to this pharmacological class.

Commonly Documented Adverse Reactions

The most frequently listed adverse reactions include those affecting the Gastrointestinal System such as indigestion (dyspepsia), heartburn, nausea, and diarrhea, which are classified as More Common or Common in regulatory documents. Central nervous system effects like headache and dizziness are also commonly documented.


Serious Adverse Reactions and System-Specific Risks

Official labeling highlights the potential for serious, class-specific adverse reactions. The Cardiovascular System is associated with the risk of thrombotic events, including myocardial infarction and stroke, which may occur early in treatment and increase with duration of use. The Gastrointestinal System carries the risk of bleeding, ulceration, and perforation, which can occur at any time during use. Severe reactions involving the Renal and Hepatic Systems, such as acute renal toxicity and severe hepatic reactions like jaundice, are also documented. Serious Dermatological/Hypersensitivity reactions, including Anaphylaxis and DRESS, are noted in the safety profile.


Population-Specific Safety Considerations

Safety constraints apply to specific populations. Older adults face a greater risk for serious gastrointestinal events. Use is generally contraindicated or strongly advised against in late pregnancy due to risks of fetal toxicity and premature closure of the fetal ductus arteriosus. The medicine is also contraindicated in patients with severe renal or hepatic impairment and in those with known hypersensitivity to aspirin or other NSAIDs.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Senta (Diflunisal) is officially documented to result in a range of clinical manifestations affecting multiple physiological systems. Documented signs and symptoms often include gastrointestinal disturbance (vomiting, diarrhea, upset stomach), tinnitus (ringing in the ears), headache, sweating, and CNS effects such as drowsiness and confusion. Physiological signs that may also be present include tachycardia (fast heart rate) and hyperventilation (fast breathing).

The regulatory profile indicates that an overdose carries the risk of severe, life-threatening outcomes, including seizures, coma (loss of consciousness), acute renal failure, and metabolic acidosis. Increased potential for unwanted effects, including those related to overdose, has been noted especially in elderly patients.

Regulator-Mandated Emergency Actions

The official guidance mandates specific actions in the event of suspected overdose. Immediately call emergency services (911) if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. The poison control helpline should also be contacted. Overdose management is based on providing symptomatic and supportive treatment. Official sources note that procedures like gastric lavage may be employed.

It is documented that no specific antidote is known for Diflunisal toxicity. Furthermore, hemodialysis may be ineffective due to the drug's high degree of protein binding.

Therapeutic Uses of Senta

What Senta Treats: Main Uses and Benefits

The therapeutic role of Senta (Diflunisal) is relevant for easing symptoms that create noticeable physiological strain across several key domains. The medication is commonly used to help with discomfort where functional stability becomes affected.

Senta is applied across domains where additional symptomatic support is needed in the management of chronic conditions, including rheumatoid arthritis and osteoarthritis. It is relevant for easing symptoms that interfere with daily functioning during acute or disruptive episodes, such as those arising from musculoskeletal trauma or temporary post-procedural pain.

In the context of systemic disease, Senta is also relevant for easing symptoms linked to organ-specific functional stress associated with transthyretin amyloidosis (ATTR). It provides support that helps ease the overall symptom burden when supportive symptom management is appropriate, which may help support general well-being during symptomatic phases.


Quick Fact: Management of Joint Pain and Symptoms related to Inflammatory or Irritative States Senta is commonly used to help manage symptoms that become more disruptive during flare-ups, such as pain, swelling, and stiffness, associated with chronic inflammatory joint conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information on Diflunisal

Eligibility and Restrictions for Use

Official Eligibility Rules for Senta (Diflunisal)

The official regulatory profile defines eligibility for Senta based strictly on age, patient history, and the status of specific organ systems.

Category Official Regulatory Statement
Populations for whom use is allowed Adults (generally 18 and older) for labeled indications (e.g., rheumatoid arthritis, osteoarthritis).
Populations for whom use is contraindicated Patients with known hypersensitivity to diflunisal or other NSAIDs. Contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Age-related eligibility rules Children younger than 12 years of age: Safety and effectiveness have not been established. Older Adults: Use requires caution due to a greater risk for serious gastrointestinal and renal events.
Condition-specific eligibility rules Contraindicated in patients with severe kidney disease / severe renal impairment and severe heart failure.
Pregnancy and lactation eligibility status Avoid use at or after 20 weeks of gestation due to fetal risk; use in the third trimester is contraindicated. Breastfeeding is generally not recommended.

Connection to the Overall Eligibility Profile

Regulatory documents establish who can and cannot use Senta by outlining absolute contraindications based on prior allergic reactions and surgical status (CABG). Non-eligibility is also defined by physiological status limitations, explicitly prohibiting use in cases of severe organ impairment. Use is formally established in adults, with the label classifying its prescription for children under 12 as use not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Senta's official interaction profile details specific combinations that may alter drug exposure or increase the risk of adverse events, as documented by regulatory authorities.

Exposure-Modifying and Contraindicated Combinations

Co-administration with Acetaminophen is associated with an approximate 50% increase in the plasma concentration of Acetaminophen due to reduced clearance. Senta also reduces the renal clearance of Methotrexate and Lithium, which can lead to elevated systemic levels and potential toxicity of these co-administered drugs; the regulatory label advises monitoring. Concomitant use with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including Ketorolac or analgesic doses of Aspirin, is generally not recommended due to a shared mechanism that increases the risk of gastrointestinal toxicity.

Pharmacodynamic and Substance Risks

When combined with oral Anticoagulants (e.g., Warfarin) or Antiplatelet agents, there is an officially documented increased risk of bleeding and hemorrhage due to additive pharmacodynamic effects. Senta may also diminish the therapeutic effect of Diuretics, ACE Inhibitors, and Angiotensin II Antagonists (ARBs), with the combination noted to potentially lead to deterioration of renal function or acute renal failure. Separately, the risk of stomach bleeding is enhanced when combined with alcohol. Specific population considerations include the heightened risk for serious gastrointestinal adverse events in elderly patients.

Mechanism of Action

Senta is a monoclonal antibody that functions as a specific inhibitor within the bone remodeling cycle. Its primary biological target is Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), a protein essential for the formation and activity of osteoclasts.

By binding to and sequestering soluble and membrane-bound RANKL, Senta prevents the ligand from engaging its receptor, RANK, on the surface of pre-osteoclast and osteoclast cells. This action effectively blocks the entire RANK/RANKL/Osteoprotegerin (OPG) axis signaling cascade, a crucial step in bone resorption.

The resultant intracellular consequence is the inhibition of osteoclast differentiation, function, and survival. This reduction in the population and activity of bone-resorbing cells leads to a system-level physiological modulation that favors bone formation over resorption, thereby altering overall bone remodeling dynamics and mineral density.

Dosage and Administration Information

Administration and Dosing Schedule

Senta is designated for oral administration only and is provided as solid tablets in 250 mg and 500 mg strengths. The dosage regimen is defined by the intended duration of use, but the total daily dose must not exceed 1500 mg.

For acute mild to moderate pain, treatment often begins with a single 1000 mg loading dose. Maintenance therapy typically requires a dose of 500 mg administered every twelve hours. For long-term symptomatic management of chronic inflammatory conditions, the usual maintenance dose ranges from 500 mg to 1000 mg total daily, taken in two divided doses.


Contextual Administration Requirements

Proper use requires specific intake conditions to be observed. The tablets must be swallowed whole and should not be crushed or chewed. To support gastric tolerability, Senta must be administered with food or milk and a full glass of water. A procedural requirement is to ensure an interval of at least two hours between taking Senta and the use of certain antacid medications, which can interfere with the systemic absorption of the drug.


Population-Specific Rules

A dose reduction is indicated in certain patient populations. For individuals with moderate impaired renal function, the dose is reduced to approximately 50% of the normal maintenance dosage to mitigate the risk of excessive drug exposure. Senta is intended for continuous use during the course of therapy for chronic conditions, adhering to the prescribed divided schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Senta (Diflunisal)

Evidence for Symptom Management in Chronic Joint Conditions

Research exploring the effects of Senta in chronic joint conditions is based on Randomized Controlled Trials (RCTs) and comparative studies. These trials were used in research exploring how symptoms change over time, and studies monitored patient-reported experiences related to physical discomfort, stiffness, and daily functioning. This evidence contributes to understanding symptom patterns in conditions marked by functional limitations.

Research in Rheumatoid Arthritis (RA)

For Rheumatoid Arthritis, studies monitored changes in outcomes related to physical discomfort over defined time intervals that were typically short-term, such as 4 to 12 weeks. Studies monitored changes in joint tenderness and the duration of morning stiffness. Research describes patterns related to changes in patient- and physician-rated assessments of disease status, as was observed in some studies with comparative treatment groups. Evidence is limited concerning long-term outcomes for RA in the core randomized trials, and data for certain groups of patients remains insufficient due to the trial's design and timing.

Research in Osteoarthritis (OA)

Senta was studied for conditions associated with acute or disruptive episodes, such as Osteoarthritis, in trials assessing short-term or episodic symptom patterns. Research explored outcomes reflecting daily functioning and patient-reported outcomes describing perceived discomfort. A key research limitation is that the available data primarily addresses symptomatic control. There is limited information for long-term outcomes that may be related to the structural progression of the underlying joint condition itself.

Evidence for Specialized Disease Management: Transthyretin Amyloidosis (ATTR)

Research for Transthyretin Amyloidosis involves a complex body of evidence. Studies monitored outcomes linked to physiological strain, including progression of nerve damage, changes in cardiac function, and the TTR protein biomarker in the blood. For the polyneuropathy subtype, studies describe patterns where the rate of decline in neurological function scores was measured during the trial period. Findings indicate patterns related to the TTR protein biomarker relevant to the condition. The certainty remains low regarding hard outcomes for the cardiomyopathy subtype, as evidence is limited to retrospective cohorts and small, non-randomized investigations.

Long-Term Research and Durability of Study Findings

Long-term effects for the majority of outcomes related to chronic symptomatic management are not fully established in controlled, blinded trials, particularly concerning durability of response or sustained effects.

Frequently Asked Questions (FAQ)

Common questions about Senta (FAQ)


Q: How is Senta different from other similar treatments?

Official documents note that Senta (diflunisal) is chemically distinguished from aspirin because it is not metabolized into salicylic acid. This difference is associated with a significantly longer plasma half-life (8 to 12 hours), which supports the drug's design for sustained therapeutic effects.

Q: Can older adults use Senta safely?

Regulatory information indicates that older adults are at a greater risk for serious gastrointestinal adverse events, such as bleeding and ulceration. Official safety information indicates that use in this population is described as requiring caution due to these documented risks, often involving monitoring.

Q: How long do people usually need to stay on Senta?

The prescribed duration of use is individualized based on the patient's condition. Regulatory documents describe its use for both short-term management of acute pain and the long-term management of chronic inflammatory conditions, such as rheumatoid arthritis.

Q: What is the risk of having an allergic reaction to Senta?

Official safety information documents the potential for serious hypersensitivity reactions, including anaphylaxis and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). A severe reaction may present as swelling or trouble breathing, and prompt medical attention is noted as necessary in such events.

Q: Why is Senta sometimes associated with liver function warnings?

Official regulatory information includes warnings about the potential for severe hepatic reactions (involving the liver), such as liver damage, also known as hepatotoxicity, or jaundice. Official documents describe that caution is required for use in people with existing liver problems.

Q: Can Senta cause weight gain?

Regulatory safety documents note that unusual or rapid weight gain is a documented possible adverse reaction. This is often listed as a potential warning sign of other systemic effects, such as fluid retention.

Q: Does Senta make you feel drowsy or tired?

Official documents list somnolence (drowsiness) as a common central nervous system adverse reaction. Tiredness is also documented as a less common effect in the official safety profile.

Q: How quickly does Senta start working after I take it?

For pain relief, official data in the clinical pharmacology section describes that significant effects are generally seen within one hour of dosing. The maximum concentration of the drug in the plasma is typically achieved between two and three hours after the first dose.

Q: Is Senta safe to take long-term?

While use for chronic conditions is established in regulatory studies, official warnings must be considered. The risk of serious cardiovascular and gastrointestinal adverse events is noted to potentially increase with the duration of use.

Q: Are there studies about Senta's effectiveness in different age groups?

Official regulatory documents indicate that the safety and effectiveness of Senta have not been established in children younger than 12 years of age. Clinical research focuses primarily on its use in adults for approved indications like rheumatoid arthritis and osteoarthritis.

Q: What is the purpose of the 'Black Box Warning' sometimes associated with Senta?

The official Boxed Warning highlights two main serious risks associated with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) like Senta. These risks are the potential for serious cardiovascular thrombotic events (like heart attack and stroke) and the risk of serious gastrointestinal adverse events (including bleeding and ulceration).

Q: Is Senta only for temporary use?

No, official information describes the medicine's use for both short-term management of acute pain and for the long-term management of certain chronic inflammatory conditions.

Q: Do I need to get regular blood tests while taking Senta?

Official patient information notes that laboratory and/or medical tests may be performed periodically. These tests are described as monitoring complete blood count and kidney and liver function to check for potential systemic effects.

Q: Why do some people say Senta causes dry mouth?

The official drug documents list 'dry mucous membranes' as a less common adverse reaction. Dry mouth is one way patients may experience and describe this documented effect.

Q: Is it normal to feel a change in appetite with Senta?

Official safety information documents 'loss of appetite' as a less common adverse reaction. If a concerning change in appetite is experienced, consultation with a healthcare professional is noted as appropriate.

Q: Can Senta be taken with other medicines for the same condition?

Official regulatory labeling advises against co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including analgesic doses of aspirin. This is due to the increased risk of gastrointestinal toxicity when these types of medicines are combined.

Q: What official sources describe the eligibility criteria for Senta?

The rules for who can and cannot use the medicine, including contraindications and use in specific populations, are established in the official U.S. Prescribing Information (such as DailyMed/FDA Label) and patient information resources (such as NIH MedlinePlus).

Q: Is it true that Senta can affect my sleep?

Official drug documents list insomnia (trouble sleeping) as a common psychiatric adverse reaction. Sleep disturbances are noted as effects that may warrant consultation with a healthcare provider.

How should Senta be stored and disposed of?

How to Store and Dispose of Senta (Diflunisal Tablets)


Storage Requirements

Senta tablets must be stored at controlled room temperature, specifically between 68 F to 77 F (20 C to 25 C). The product must be protected from excessive heat, moisture, and direct light. It is prohibited to refrigerate, store in the freezer, or allow the tablets to freeze.

The medication must remain in its original container with the cap tightly closed. To prevent accidental harm, the tablets must always be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Senta must be disposed of properly. Consult a healthcare professional or pharmacist for disposal instructions, with drug take-back programs being the preferred option. The tablets must not be flushed down a toilet or poured into a drain. If a take-back program is unavailable, dispose of the medicine by mixing it with an unappealing substance, placing it in a sealed container, and discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Senta found in:

A-Z Index: